Sign up Australia
Proactive Investors - Run By Investors For Investors

3D Medical: Mach7 Technologies granted mobile device image capture patent

3D Medical: Mach7 Technologies granted mobile device image capture patent

3D Medical (ASX:3DM) and Mach7 Technologies Pte. Ltd which recently announced an intention to merge have been awarded a U.S. patent for its technology that acquires medical image data from a mobile device and sends that data for patient medical record upload.

The Mach7 technology puts mobile healthcare in the hands of patient-facing clinicians and moves image management closer to the point of care delivery.

This reduces time to diagnose and helps ensure faster care delivery.

Around 60% of medical imaging data is captured outside of digital imaging departments such as radiology and cardiology.

Outside of these two groupings, medical facilities face an uphill battle to optimise workflow to capture medical imaging data digitally and to store and share the data through a patient’s EMR.

Subject to approvals and capital raisings of $10 million, 3D Medical and Mach7 Technologies will change the ASX listed entity name to Mach7 Technologies Limited.

The first $4 million was raised in a placement at $0.075 each while a share purchase plan is also planned.

3D Medical prints 3D models of a patients bones and organs for doctors and surgeons. Mach7 is a United States medical technology business.

3D Medical was the Australian reseller of Mach7's imaging platform.


Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

Register here to be notified of future M7T Company articles
View full M7T profile

Mach7 Technologies Timeline

November 14 2016
November 30 2015

Related Articles

January 10 2017
We look at what looks to be a savvy investment by the UK biotech.
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
newspaper with word cancer magnified
January 30 2017
The start of 2017 has seen some good trial results for its skin cancer treatment, as well as a collaboration deal that will accelerate the development of its lung cancer drug

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.